Efruxifermin Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Efruxifermin comprises 2 peer-reviewed publications across 2 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Non-alcoholic Fatty Liver Disease. Most recent publication: Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial., Lancet, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Noureddin M, Frias JP, Neff GW, et al. · Lancet · 2025
    PubMed: PMID 40818852 · NCT04767529 (Harmony) · Non-alcoholic Fatty Liver Disease
  2. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Harrison SA, Frias JP, Neff G, et al. · Lancet Gastroenterol Hepatol · 2023
    PubMed: PMID 37802088 · NCT04767529 (Harmony) · Non-alcoholic Fatty Liver Disease

Publications by year

2023–2025: 2 publications.

2023
1
2025
1

Publications by indication

Non-alcoholic Fatty Liver Disease (2)

  • Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Lancet · 2025 · PMID 40818852 · NCT04767529
  • Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Lancet Gastroenterol Hepatol · 2023 · PMID 37802088 · NCT04767529

Publications by journal

  • Lancet1 paper
  • Lancet Gastroenterol Hepatol1 paper

All Efruxifermin publications (2)

2025 (1 paper)

  1. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Noureddin M, Frias JP, Neff GW, et al. · Lancet · 2025 · Derived
    PubMed: PMID 40818852 · NCT04767529 (Harmony) · Non-alcoholic Fatty Liver Disease

2023 (1 paper)

  1. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Harrison SA, Frias JP, Neff G, et al. · Lancet Gastroenterol Hepatol · 2023 · Background
    PubMed: PMID 37802088 · NCT04767529 (Harmony) · Non-alcoholic Fatty Liver Disease

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Thu, 14 May 2026 22:21:40 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).